chronic fatigue syndrome

chronic fatigue syndrome is a complex, long-term medical condition characterized by profound, debilitating fatigue that is not improved by rest and is worsened by physical or mental activity. This post-exertional malaise is a core feature, alongside a constellation of other symptoms affecting multiple bodily systems. Diagnosis is clinical, relying on specific criteria such as the International Consensus Criteria or those from the U.S. Centers for Disease Control and Prevention, after excluding other medical and psychiatric illnesses. The condition, also termed myalgic encephalomyelitis or systemic exertion intolerance disease, represents a significant challenge to global healthcare systems.

Definition and diagnosis

There is no single definitive test, so diagnosis is based on meeting defined clinical criteria. The most widely used criteria historically were from the U.S. Centers for Disease Control and Prevention, often called the Fukuda criteria, which require six months of unexplained fatigue and several concurrent symptoms. More recent definitions, like the International Consensus Criteria and the National Academy of Medicine criteria, place greater emphasis on post-exertional malaise and neurological impairments. Diagnosis requires a thorough evaluation by a physician, often a specialist in internal medicine or neurology, to rule out conditions with similar presentations such as thyroid disease, sleep apnea, Major depressive disorder, and autoimmune diseases like Lupus erythematosus.

Signs and symptoms

The primary symptom is a severe, persistent fatigue profoundly different from normal tiredness. The hallmark is post-exertional malaise, where even minor physical or cognitive exertion leads to a debilitating worsening of symptoms that can last for days or weeks. Other common symptoms include unrefreshing sleep, cognitive dysfunction often described as "brain fog," orthostatic intolerance such as neurally mediated hypotension, muscle and joint pain, sore throat, and tender lymph nodes. Many patients also experience sensitivities to light, sound, and chemicals. The symptom severity can fluctuate and often leads to significant functional impairment.

Causes and pathophysiology

The exact cause remains unknown, but research points to a multifactorial origin, often triggered by an infection. Potential infectious triggers include Epstein-Barr virus, human herpesvirus 6, enteroviruses, and Ross River virus. Research implicates abnormalities in the immune system, such as chronic inflammation and altered cytokine profiles. Neurological studies suggest dysfunction in the autonomic nervous system and hypothalamic-pituitary-adrenal axis. There is also evidence of impaired cellular energy production, with studies at institutions like the National Institutes of Health pointing to mitochondrial dysfunction. Genetic predisposition is being investigated through studies like the UK Biobank.

Management and treatment

There is no cure, so management focuses on symptom relief and improving function. A key strategy is pacing, which involves carefully balancing activity and rest to avoid triggering post-exertional malaise. Historically, graded exercise therapy and cognitive behavioral therapy were widely recommended, particularly following the PACE trial, but their application is now controversial. Pharmacological treatments are symptomatic and may include drugs for pain, sleep disturbances, and orthostatic intolerance. Some patients report benefit from low-dose naltrexone or rituximab, though the latter's efficacy was not confirmed in a trial by the Norwegian University of Science and Technology. Care is often coordinated through specialized clinics like those at the Stanford University School of Medicine.

Prognosis and epidemiology

The prognosis is highly variable; full recovery is rare, especially in severe cases. Some patients experience a fluctuating course with periods of relative improvement, while others may progressively worsen. The condition affects an estimated 0.2–0.4% of the population globally, with prevalence studies conducted by organizations like the World Health Organization confirming it as a significant public health issue. It is more commonly diagnosed in women than in men and can occur at any age, including in children and adolescents. Severe cases can lead to being largely housebound or bedridden, as documented by patient advocacy groups like #MEAction.

History and controversy

The condition gained prominence in the 1980s following outbreaks in locations such as Incline Village at Lake Tahoe, leading to initial media labeling as "yuppie flu." The naming has been contentious, with patient advocates strongly favoring myalgic encephalomyelitis, a term used notably after an outbreak at the Royal Free Hospital in London. Major controversy has surrounded research and treatment recommendations, most notably the PACE trial, whose methodology and conclusions were heavily criticized by patients and many scientists. Advocacy by groups like the Solve ME/CFS Initiative has pushed for increased research funding, leading to renewed efforts by the National Institutes of Health and the U.S. Centers for Disease Control and Prevention. Category:Neurological disorders Category:Immune system disorders Category:Chronic diseases